Products from BPS Bioscience require a minimum order value above 400€Application: Monitor the TACI/NF-κB signaling pathway activity in a cellular model.Screen for compound activity on the TACI/NF-κB signaling pathway.
Background: TACI (transmembrane activator and CAML interactor), also known as Tumor necrosis factor receptor superfamily member 13B (TNFRSF13B) or CD267, is a type I membrane protein encoded by the TNFRSF13B gene. TACI belongs to the TNF receptor superfamily of proteins found in B cells and is a cell surface receptor for APRIL (A proliferation-inducing ligand, also known as TNFSF13) and BAFF (B-cell activating factor, also known as TNFSF13B, TALL1 or BLYS), binding both ligands with similar high affinity. TACI, BCMA (B-cell maturation antigen) and BAFFR are expressed at different stages of B cell development, with TACI being present in marginal zone, switched memory B cells and plasma cells. TACI is upregulated in activated B cells and is constitutively shed from the cell surface by ADAM10 (disintegrin and metalloprotease), resulting in a decoy receptor that is soluble. The levels of decoy receptor seem to correlate with some auto-immune disorders, such as SLE (systemic lupus erythematosus). Its role in auto-immune disorders led to the development of strategies around it, such as atacicept, a recombinant protein that blocks TACI-related signaling. High levels of TACI are also found in myeloma cells, and studies with CAR (chimeric antigen receptor)-T cells targeting TACI and BCMA, with the goal to bypass antigen escape when performing single antigen targeting, are underway for MM (multiple myeloma).
Description: The BAFF/APRIL Responsive TACI-NF-κB Luciferase Reporter HEK293 Cell Line is a HEK293 cell line that expresses full-length human TACI (transmembrane activator and CAML interactor, also known as Tumor necrosis factor receptor superfamily member 13B or CD267) (NM_012452.3) under the control of a CMV promoter, for high constitutive expression, and an inducible firefly luciferase reporter controlled by the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) Response Element located upstream of a minimal promoter. Upon ligand binding, TACI will initiate the NF-κB signaling pathway, leading to expression of the NF-κB-controlled luciferase reporter. This cell line has been validated by flow cytometry and has been shown to respond to BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand).
Interested in screening and profiling inhibitors, blocking antibodies, or activators of TACI signaling without the need to purchase and license the cell line? Check out our
Cell Signaling Pathway Screening.Genbank: NM_012452.3
Host Cell Line: HEK293, Human Embryonic Kidney, epithelial-like cells, adherent
Mycoplasma Testing: The cell line has been screened to confirm the absence of Mycoplasma species.
Storage Stability: Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage.
Supplied As: Each vial contains ˃1 X 10
6 cells in 1 ml of Cell Freezing Medium (BPS Bioscience #79796)
Uniprot: O14836
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: BSL-2
References:
Smulski C., et al., 2017 Cell Reports 18(9): P2189-2202.
Larson R., et al., 2023 Nature Communications 14: 7509.
Deutsch
English
